Indication
Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Loading your page…
Loading your page…
Multiple Sclerosis, Relapsing-Remitting
Marketing Authorisation Holder: Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
EMA Authorisation: 13/05/2022
INN: dimethyl fumarate
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dimethyl fumarate Polpharma: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.